Medigen, BlueWillow collaborate to develop SARS-CoV-2 intranasal vaccine

This article was originally published here

According to BlueWillow Biologics, the preclinical research shown that the company’s nasal vaccine adjuvant combined with Medigen’s S-2P spike protein enabled to significantly neutralise antibody response. The research

The post Medigen, BlueWillow collaborate to develop SARS-CoV-2 intranasal vaccine appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply